Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

GH - Guardant Health, Inc. So'nggi Yangiliklar | Finranks

Home

/

GH

G

Guardant Health, Inc. (GH)

NMS – Real vaqt narxi. Valyuta: USD

163.34

-1.75 (-1.06%)

Bozor ochiq: Aug 12, 2026, 3:23 PM EDT

165.20

+0.11 (0.07%)

Oldingi bozordan keyin: Aug 11, 2026, 7:39 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Guardant Health: Screening And MRD Are Just Getting Started

Guardant Health: Screening And MRD Are Just Getting Started

Guardant Health is experiencing robust growth, driven by its MRD and screening businesses. Recent FDA approvals, expanded reimbursement, and inclusion in clinical guidelines should help to ensure growth remains strong going forward. Competition in both screening and MRD monitoring is set to intensify in coming years, though.

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 46,044 shares of its common stock to 149 new non-executive employees with a grant date of August 3, 2026, under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs.

Alger Small Cap Focus Fund Q2 2026 Portfolio Review

Alger Small Cap Focus Fund Q2 2026 Portfolio Review

Nebius Group, Credo Technology Group, and Guardant Health, Inc. were among the top contributors to performance. During the quarter, Credo shares contributed positively to performance as investors responded favorably to the company's rapid revenue growth and rising demand from hyperscale customers. Karman Holdings Inc., GeneDx Holdings Corp., and Forte Biosciences Inc. were among the top detractors from performance.

GE Aerospace, AI Play Lead Five Stocks Near Buy Points

GE Aerospace, AI Play Lead Five Stocks Near Buy Points

Three of these watchlist stocks have already passed their earnings tests.

Biotech company launches multi-cancer detection test

Biotech company launches multi-cancer detection test

Guardant Health co-founder and co-CEO Helmy Eltoukhy discusses his company's blood test for colorectal cancer on ‘The Claman Countdown.'

Videolar

Biotech company launches multi-cancer detection test

Press-relizlar

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 46,044 shares of its common stock to 149 new non-executive employees with a grant date of August 3, 2026, under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs.